Skye Bioscience Expands Cannabinoid Pharmaceutical Innovation Program with Leading Cannabinoid Medicinal Chemistry Groups
Ryan Allway
June 7th, 2022
News, Top News
New collaborations focused on building library of novel cannabinoid derivatives and small molecules capable of modulating endocannabinoid system
San Diego, California, June 07, 2022 (GLOBE NEWSWIRE) — Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing proprietary, synthetic cannabinoid derivatives to treat glaucoma and other diseases with significant unmet needs, has signed new research agreements with the University of Eastern Piedmont (UPO) in Italy and the Spanish Research Council (CSIC) that will focus on developing an extensive library of novel molecules designed to modulate the endocannabinoid system (ECS), with an initial focus on ophthalmic disorders.
Skye launched its Cannabinoid Pharmaceutical Innovation Program (CPIP) in October 2021 to expand its cannabinoid-based science and cutting-edge research that can be commercialized through new and existing technologies. These new collaborations are intended to help build and screen a library of up to 100 molecules in the first year. The novel molecules will be screened using a proprietary screening platform developed by Skye to analyze key molecular targets related to a range of disease pathways.
The agreement with UPO is a contract research agreement (CRA) focused on the synthesis of novel derivatives of both major and minor phytocannabinoids. Skye will sponsor the research and all intellectual property developed under this CRA will be solely owned by Skye.
Heading the research is Diego Caprioglio, PhD, professor in the Department of Pharmaceutical Sciences’ Novara Natural Product Chemistry Group (Novara) at UPO. At Novara, Dr. Caprioglio trained under Giovanni Appendino, a pioneer in the field of phytocannabinoid chemistry. Novara’s research takes inspiration from natural products to solve problems in organic chemistry with new synthetic methodologies; in cell biology, with novel mechanisms of action; and in medicine, with new drug candidates. Dr. Caprioglio has studied and developed novel potent molecules capable of interacting with the endocannabinoid system, with research ranging from non-classical cannabinoids such as beta-caryophyllene to major and minor phytocannabinoids. He has authored over 30 peer-reviewed publications and is an inventor on a number of patents related to the chemistry and bioactivity of natural products.
The relationship with CSIC is two-pronged. The first prong is a material transfer agreement with an option for an exclusive license of existing molecules targeting major cannabinoid receptors as well as other receptors known to play a role in ECS signaling. The second prong is a CRA in which Skye is sponsoring the development of novel small molecule compounds targeting cannabinoid and other G protein-coupled receptors related to the ECS. Skye will retain all intellectual property developed under the CRA.
Heading this project is Nadine Jagerovic, PhD, at The Medicinal Chemistry Institute (IQM), in Madrid, Spain, a division of the Spanish Research Council focused on the discovery and optimization of bioactive molecules for treatment, characterization, and diagnosis of different diseases. Over the last 15 years, her scientific interest has been focused on the discovery of modulators of G protein-coupled receptors related to the ECS. Her current research is concerned with the endogenous cannabinoid and opioid systems. She is a co-author of more than 120 peer-reviewed publications in international journals and is a co-inventor of 15 patents.
“Fundamental to Skye’s strategy for differentiation is developing a pipeline of molecules that retain the potential therapeutic benefit of cannabinoids but are chemically distinct, patentable, and synthetically manufactured. Importantly, our aim is to discover and develop these molecules into validated clinical candidates that can expand Skye’s future clinical pipeline or be licensed to potential pharmaceutical partners,” said Tu Diep, Chief Development Officer of Skye. “Partnering with academic centers of excellence in cannabinoid research is a key pillar of this pharmaceutical development strategy. These scientific collaborations with leading research institutes, and with Drs. Caprioglio and Jagerovic and their established cannabinoid research initiatives, will add new technology as well as new thinking and capabilities to our discovery efforts.”
“We launched our Cannabinoid Pharmaceutical Innovation Program with the intent to form a strong collaborative network of research knowledge and effort and are pleased to build on our core agreement with VivaCell Biotechnology España and Dr. Eduardo Muñoz,” said Punit Dhillon, CEO and Chair of Skye. “As we continue with our priority focus of transitioning into Phase 1 with our lead drug candidate, SBI-100 Ophthalmic Emulsion, these new steps strengthen our research to more broadly address the many challenges in ophthalmology treatment.”
About Skye Bioscience, Inc.
Skye Bioscience, Inc. is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs. The Company’s lead program, SBI-100 Ophthalmic Emulsion, is being developed as a potential treatment for glaucoma, the world’s leading cause of irreversible blindness. For more information, please visit www.skyebioscience.com.
CONTACT
Investor Relations
Email: ir@skyebioscience.com
Phone: (858) 410-0266
FORWARD LOOKING STATEMENTS
This letter contains forward-looking statements, including statements regarding our product development, business strategy, the timing of clinical trials, and commercialization of cannabinoid-derived therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management’s current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition, and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including “anticipated,” “plans,” “goal,” “focus,” “aims,” “intends,” “believes,” “can,” “could,” “challenge,” “predictable,” “will,” “would,” “may” or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment, and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Company may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Skye’s most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Skye disclaims any intent or obligation to update these forward-looking statements.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
About Ryan Allway
Mr. Allway has over a decade of experience in the financial markets as both a private investor and financial journalist. He has been actively involved in the cannabis industry since its inception, covering public and private companies.
Search CannabisFN
Press Coverage
Psychedelics Index
Top Videos
Watch CFN Media’s exclusive three part interview with Paul Rosen, one of the most active and diversified investors in the emerging cannabis industry. Paul gives his insights on the global cannabis industry and discusses his new endeavors. Become a CFN Media Client Paul Rosen is a noted career entrepreneur and management consultant. Over the last […]
Technical420 is the premier provider of research and analysis on cannabis stocks. We provide investors with sponsored and non-sponsored information on the volatile and emerging cannabis industry. “Our research is our passion!” Your profit is our reward!
Chemesis International is a vertically integrated global leader in the cannabis industry, currently operating within Puerto Rico, and California.
The Gluu is the first ever distribution platform serving the larger cannabis industry, linking together suppliers, manufacturers, reps, retailers and customers. If you sell products think of us as the B2B Amazon of the industry.
Network Partners
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.
Copyright © Accelerize Inc. · All Rights Reserved · Privacy Policy · Legal Disclaimer
